How Vaccines Work: The Science of Immunization

The Immunological Principle Behind Vaccination

Vaccination works because the adaptive immune system remembers every antigen it has ever encountered. During a natural infection, the immune system takes 7 to 14 days to mount a full primary response, producing antigen-specific T cells and antibodies. During this lag period, the pathogen multiplies, damages tissues, and causes symptoms. A vaccine compresses this learning phase by presenting antigens in a safe context, allowing the immune system to build memory without the dangers of actual infection.

When a vaccinated person later encounters the real pathogen, memory B cells and memory T cells recognize the familiar antigens and mount a secondary response within 1 to 3 days. The secondary response produces antibodies at concentrations 10 to 100 times higher than the primary response, and these antibodies bind their targets with much greater affinity thanks to the affinity maturation that occurred during the initial vaccination response. This rapid, amplified reaction typically eliminates the pathogen before it can replicate enough to cause symptoms or significant tissue damage.

The quality of vaccine-induced immunity depends on several factors: the type and amount of antigen presented, the presence of adjuvants (substances that enhance the immune response), the route of administration, and the vaccination schedule. Booster doses are often necessary because some vaccines do not generate long-lasting memory on their own, or because the pathogen mutates rapidly enough that the immune response needs to be updated. The annual influenza vaccine, for example, is reformulated each year to match circulating viral strains.

Types of Vaccine Platforms

Vaccine technology has evolved dramatically since Edward Jenner's cowpox experiments in 1796. Modern vaccines fall into several major categories, each with distinct advantages and limitations.

Live attenuated vaccines contain weakened versions of the pathogen that can replicate in the body but are unable to cause disease in healthy individuals. The measles, mumps, and rubella (MMR) vaccine, the oral polio vaccine (OPV), the varicella (chickenpox) vaccine, and the yellow fever vaccine are all live attenuated vaccines. Because the weakened pathogen replicates and produces a broad range of antigens, these vaccines tend to generate strong, long-lasting immunity, often with a single dose. The limitation is that they cannot be given to immunocompromised individuals, since even a weakened pathogen can cause disease in someone whose immune system is severely impaired.

Inactivated vaccines contain pathogens that have been killed by heat, chemicals (typically formaldehyde or beta-propiolactone), or radiation. The inactivated polio vaccine (IPV), the hepatitis A vaccine, and the seasonal influenza shot (in its traditional form) use this approach. Because the pathogen is dead and cannot replicate, inactivated vaccines are safer than live vaccines but generally produce weaker immune responses. They typically require multiple doses and periodic boosters to maintain protective immunity, and they tend to generate stronger antibody responses than T cell responses.

Subunit vaccines contain only specific proteins, peptides, or polysaccharides from the pathogen, rather than the whole organism. The hepatitis B vaccine, for example, contains the viral surface antigen (HBsAg) produced by yeast cells through recombinant DNA technology. The human papillomavirus (HPV) vaccine contains virus-like particles (VLPs), self-assembling protein shells that mimic the virus structure but contain no genetic material. Subunit vaccines are extremely safe because they contain no living or complete pathogen, but they typically require adjuvants to generate adequate immune responses and may need multiple doses.

Conjugate vaccines address the challenge of immunizing against bacterial polysaccharide capsules, which are poor at stimulating T cell help and therefore generate weak immune responses, especially in young children. In a conjugate vaccine, the polysaccharide antigen is chemically linked to a carrier protein, such as diphtheria toxoid or tetanus toxoid. This conjugation converts a T cell-independent antigen into a T cell-dependent one, enabling germinal center reactions, affinity maturation, and immunological memory. The Haemophilus influenzae type b (Hib) vaccine, the pneumococcal conjugate vaccine (PCV13/PCV20), and the meningococcal conjugate vaccines all use this technology. Conjugate vaccines have dramatically reduced the incidence of invasive bacterial diseases in children.

Toxoid vaccines target bacterial diseases caused by toxins rather than by the bacteria themselves. Diphtheria and tetanus vaccines contain inactivated forms of the bacterial toxins (called toxoids) that stimulate the production of antitoxin antibodies. These antibodies neutralize the toxin upon exposure, preventing disease even if the bacteria themselves are present.

mRNA Vaccines: A New Platform

Messenger RNA (mRNA) vaccines represent one of the most significant advances in vaccine technology in decades. Rather than delivering a pathogen or pathogen protein directly, mRNA vaccines deliver synthetic mRNA encoding a target protein, which the body's own cells then produce. The Pfizer-BioNTech and Moderna COVID-19 vaccines, the first mRNA vaccines authorized for human use, encode the SARS-CoV-2 spike protein. After injection, lipid nanoparticles carrying the mRNA are taken up by cells near the injection site, which translate the mRNA into spike protein. The spike protein is displayed on the cell surface and recognized by the immune system as foreign, triggering robust antibody and T cell responses.

mRNA vaccines have several important advantages. They can be designed and manufactured rapidly once the genetic sequence of the target protein is known, since no pathogen cultivation is required. The Moderna COVID-19 vaccine sequence was finalized within 2 days of the SARS-CoV-2 genome being published in January 2020, and clinical trials began 66 days later. The mRNA is transient: it is translated into protein for 24 to 72 hours, then degraded by normal cellular enzymes. It does not enter the cell nucleus and cannot integrate into the host genome.

The technology required decades of foundational research before it became clinically viable. Key breakthroughs included Katalin Kariko and Drew Weissman's discovery that replacing uridine with pseudouridine in synthetic mRNA dramatically reduces the inflammatory response and increases protein production, and the development of lipid nanoparticle delivery systems that protect the fragile mRNA molecule and enable its uptake by cells. These advances earned Kariko and Weissman the 2023 Nobel Prize in Physiology or Medicine.

mRNA vaccines are now being developed for influenza, respiratory syncytial virus (RSV), Epstein-Barr virus, HIV, malaria, and multiple types of cancer. Personalized cancer vaccines, in which a patient's tumor is sequenced and an mRNA vaccine encoding tumor-specific neoantigens is manufactured and administered, are in clinical trials and have shown promising early results in melanoma and pancreatic cancer.

Adjuvants: Boosting the Immune Response

Many vaccines require adjuvants, substances that enhance the immune response to the vaccine antigen. The most widely used adjuvant is aluminum salts (alum), which has been included in vaccines since the 1920s. Alum works by creating a depot effect, slowly releasing antigen from the injection site over days to weeks, and by activating the innate immune system through the NLRP3 inflammasome, promoting dendritic cell maturation and antigen presentation.

Newer adjuvant systems include AS01 (used in the Shingrix shingles vaccine and the RTS,S malaria vaccine), which contains monophosphoryl lipid A (a TLR4 agonist) and QS-21 (a saponin), and MF59 (used in the Fluad influenza vaccine), an oil-in-water emulsion that enhances antigen uptake by immune cells. These modern adjuvants can direct the immune response toward specific types of immunity, for example promoting Th1 responses for intracellular pathogens or Th2 responses for extracellular targets.

The mRNA vaccines did not require traditional adjuvants because the lipid nanoparticle delivery system and the mRNA itself provide built-in adjuvant effects. The ionizable lipids in the nanoparticle activate innate immune sensors, and the mRNA, even with nucleoside modifications, retains some ability to stimulate pattern recognition receptors, providing the "danger signals" needed to initiate a robust adaptive response.

Herd Immunity and Population Protection

Herd immunity occurs when a sufficient proportion of a population is immune to a pathogen, either through vaccination or prior infection, that the pathogen cannot sustain transmission. Individuals who are not immune, including those who cannot be vaccinated due to age, immunodeficiency, or medical contraindications, are indirectly protected because the pathogen has too few susceptible hosts to maintain a chain of infection.

The herd immunity threshold depends on the pathogen's basic reproduction number (R0), the average number of secondary infections produced by a single infected individual in a fully susceptible population. The formula is straightforward: the minimum proportion immune needed is 1 - (1/R0). Measles, with an R0 of 12 to 18, requires 92 to 95 percent population immunity. Polio (R0 of 5 to 7) requires about 80 to 86 percent. Seasonal influenza (R0 of 1.5 to 2) requires about 33 to 50 percent. These thresholds are why maintaining high vaccination coverage is critical for preventing outbreaks, and why even small declines in vaccination rates can lead to disease resurgence.

The global impact of vaccination is staggering. Smallpox was eradicated in 1980 through a worldwide vaccination campaign, the only human disease ever eliminated entirely. Polio cases have decreased by over 99 percent since the Global Polio Eradication Initiative began in 1988. Measles deaths dropped by 73 percent between 2000 and 2018 due to expanded vaccination coverage. The WHO estimates that vaccines prevent 3.5 to 5 million deaths annually from diseases including diphtheria, tetanus, pertussis, influenza, and measles.